Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing. (2018)

Peer-Reviewed Study · Jenny Rubin; Sharmineh Mansoori; Kristin Blom et al. · July 20, 2018

Jenny Rubin et al., 2018-07-20: Follow-up study showing mebendazole increases IFN-gamma, TNF-alpha and other cytokines in TCR-activated PBMC co-cultures and increases killing of lung cancer cells, an effect requiring CD14+ monocytes.

This effect was dependent on the presence of CD14 monocytes/macrophages in the co-culture.

Jenny Rubin et al., 2018-07-20: Follow-up study showing mebendazole increases IFN-gamma, TNF-alpha and other cytokines in TCR-activated PBMC co-cultures and increases killing of lung cancer cells, an effect requiring CD14+ monocytes. Study type: human PBMC/tumour co-cultures. N: not applicable (donor PBMCs). Country: Sweden (Uppsala University). Dose: 0.3-10 micromolar, described as clinically achievable. Funder: 'The present work were funded only by academic grants' (per the group's disclosure wording). Declared conflicts: 'RL, PN and MF are co-founders and shareholders of Repos Pharma AB… AL is chairman of the board.' Comparator: PBMC co-cultures without mebendazole, and CD14-depleted cultures.